Log in
NASDAQ:SPRB

Spruce Biosciences Stock Forecast, Price & News

$21.89
-0.09 (-0.41 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$21.25
Now: $21.89
$22.43
50-Day Range N/A
52-Week Range
$15.12
Now: $21.89
$22.51
Volume65,925 shs
Average Volume139,128 shs
Market Capitalization$487.36 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was founded in 2014 and is headquartered in Daly City, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.60 out of 5 stars

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SPRB
CUSIPN/A
CIKN/A
Phone415-294-1687
Employees15

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$487.36 million
Next Earnings DateN/A
OptionableNot Optionable
$21.89
-0.09 (-0.41 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SPRB News and Ratings via Email

Sign-up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Spruce Biosciences (NASDAQ:SPRB) Frequently Asked Questions

Who are some of Spruce Biosciences' key competitors?

Who are Spruce Biosciences' key executives?

Spruce Biosciences' management team includes the following people:
  • Mr. Michael G. Grey, Exec. Chairman (Age 67)
  • Mr. Richard A. King M.B.A., CEO & Director (Age 55)
  • Mr. Samir M. Gharib CPA, M.B.A., CPA, Chief Financial Officer (Age 38)

When did Spruce Biosciences IPO?

(SPRB) raised $75 million in an IPO on Friday, October 9th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets served as the underwriters for the IPO.

What is Spruce Biosciences' stock symbol?

Spruce Biosciences trades on the NASDAQ under the ticker symbol "SPRB."

When does the company's quiet period expire?

Spruce Biosciences' quiet period expires on Wednesday, November 18th. Spruce Biosciences had issued 6,000,000 shares in its IPO on October 9th. The total size of the offering was $90,000,000 based on an initial share price of $15.00. During the company's quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Spruce Biosciences?

Shares of SPRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Spruce Biosciences' stock price today?

One share of SPRB stock can currently be purchased for approximately $21.89.

How big of a company is Spruce Biosciences?

Spruce Biosciences has a market capitalization of $487.36 million. Spruce Biosciences employs 15 workers across the globe.

What is Spruce Biosciences' official website?

The official website for Spruce Biosciences is www.sprucebiosciences.com.

How can I contact Spruce Biosciences?

The company can be reached via phone at 415-294-1687.

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.